Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial

BACKGROUND: Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist spironolactone can improve exercise capacity, E...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Heart Assoc
Autori principali: Shantsila, Eduard, Shahid, Farhan, Sun, Yongzhong, Deeks, Jonathan, Calvert, Melanie, Fisher, James P., Kirchhof, Paulus, Gill, Paramjit S., Lip, Gregory Y. H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726985/
https://ncbi.nlm.nih.gov/pubmed/32909497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.016239
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi